Marshall Wace North America L.P. trimmed its holdings in Syneos Health Inc (NASDAQ:SYNH) by 79.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,044 shares of the company’s stock after selling 214,557 shares during the quarter. Marshall Wace North America L.P. owned approximately 0.05% of Syneos Health worth $2,952,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the company. NumerixS Investment Technologies Inc acquired a new stake in Syneos Health in the fourth quarter valued at approximately $57,000. Bessemer Group Inc. acquired a new stake in Syneos Health in the fourth quarter worth $59,000. Oppenheimer Asset Management Inc. acquired a new stake in Syneos Health in the fourth quarter worth $66,000. AlphaOne Investment Services LLC increased its position in Syneos Health by 29.0% in the first quarter. AlphaOne Investment Services LLC now owns 1,590 shares of the company’s stock worth $82,000 after buying an additional 357 shares during the period. Finally, Bank of Montreal Can increased its position in Syneos Health by 70.7% in the fourth quarter. Bank of Montreal Can now owns 2,539 shares of the company’s stock worth $99,000 after buying an additional 1,052 shares during the period.
Several brokerages have weighed in on SYNH. ValuEngine raised Yandex from a “hold” rating to a “buy” rating in a research report on Saturday, April 13th. Credit Suisse Group set a GBX 190 ($2.48) price target on Barclays and gave the company a “neutral” rating in a report on Tuesday, March 19th. UBS Group lowered Huaneng Power International Inc ADR Class N from a “neutral” rating to a “sell” rating in a report on Tuesday, March 19th. William Blair reaffirmed a “market perform” rating on shares of NationalResearchCorp . in a report on Tuesday, March 19th. Finally, Wolfe Research initiated coverage on Iqvia in a report on Tuesday, April 2nd. They set a “market perform” rating on the stock. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Syneos Health has a consensus rating of “Buy” and a consensus price target of $53.33.
Syneos Health (NASDAQ:SYNH) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.08. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Syneos Health had a return on equity of 9.55% and a net margin of 0.42%. Syneos Health’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.55 EPS. As a group, sell-side analysts anticipate that Syneos Health Inc will post 2.66 earnings per share for the current year.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Story: Dividend Achievers
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.